Greater discovery is enabled when data from individual disease and cohort studies can be homogenized and linked together, revealing biological commonalities and differences across diverse populations and diseases.
Sapient has built an expansive Human Biology Database for this purpose, comprised of data from 100,000+ human biosamples from individuals and studies around the world. The samples have been assayed using our rapid liquid chromatography-mass spectromerty (rLC-MS) platform for untargeted small molecule biomarker discovery, measuring over 15,000 circulating factors in each sample.
Download this fact sheet to learn more about this database for biomarker discovery – which includes disease-centric data for more than 60 diseases and disorders, linked with longitudinal information on individuals that have been clinically followed for a range of 10-30 years – and how it can be mined to rapidly identify, validate, and translate novel biomarker discoveries.